ERBB2 and breast cancer: Therefore, our comparative study of HercepTest (mAb) with PATHWAY 4B5 addresses the main challenges that may arise during HER2 testing in BC, particularly with consideration to the emerging anti-HER2-directed drugs and patients with lower HER2 expression.